Protide Pharmaceuticals, Inc. Stock

Protide Pharmaceuticals, Inc. is engaged in the discovery, development and advancement of technologies and processes in clinical cell therapy, regenerative medicine, transplantation and cell engineering. The Company offers a range of products, including serum replacements, cryopreservatives, cell processing and cell islet transplantation (CIT) islet cell solutions. The Company's serum replacements product enables insight into cellular processes, as well as commercial production of recombinant therapeutic proteins, vaccines and other biological proteins. Its serum replacements product includes TCH, VaxMax, HemaPro, TM-235 and TCM. Its cryopreservatives products include Stemsol USP (DMSO), pZerve, Cellvation, MiCord 55% DMSO USP 5% Dextran USP and 2-8CELLsius + DMSO. Its cell processing products include 2-8CELLsius, Dextran 40 in 0.9% NaCl, Dulbecco's Phosphate Buffered Saline (10X) PBS, Dulbecco's Phosphate Buffered Saline (1X) PBS and Hank's Balanced Salt Solution (1X) HBSS.